Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*
Asia-Pacific Hospital-Acquired Infection Diagnostics Market By Product (Instrument and Reagents & Consumables) By Infection Type (Procedural Sedation, Pain Management, Emergency Medicine, Critical Care, General Floor, and Others), By Test Type (Molecular Diagnostics, Urinalysis, And Immunoassay) and End Use (Hospitals, Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
| A08861 | Pages: 228 | Dec 2020 | 136 Views | | |
| Author(s) : Ravi Telugunta, Apoorva Srivastava , Onkar Sumant | Tables: 91 | Charts: 48 | Formats*: | |
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Asia-pacific Hospital-acquired Infection Diagnostics Market
Request Now !The Asia-Pacific hospital-acquired infection diagnostics market accounted for $418.937 million in 2019, and is expected to reach $780.882 million by 2027, registering a CAGR of 7.5% from 2020 to 2027.
Due to Covid-19, the development of easy-to-use and rapid devices to support testing outside of laboratory settings for Covid-19 has been a response of diagnostic test manufacturers to shortage of laboratory-based molecular testing capacity. which is expected to hamper the market.
Hospital-acquired infections (HAIs) are type of infections acquired during hospitalization and are commonly known as nosocomial infection. These infections can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can be acquired from an infected patient, outside environment, or from a staff of that facility. The hospital-acquired infection diagnostics market is primarily driven by the growth in awareness among healthcare workers and proposed government initiatives by many governmental organizations. Further, in the developing economies such as China, India, and Brazil, the cleanliness and hygiene is minimum. Hence, it results in more hospital-acquired infections, which further increases the demand for hospital-acquired infection diagnostics. However, the increase in healthcare cost and prevalence of antibiotic resistant infections impede the market growth.
Get more information on this report : Request Sample Pages
A majority of hospitals in APAC (approx. 70%) expect pharma and medical device manufacturers to maintain or increase on-site presence and support for new product training, but decrease their presence and support for sales detailing and service support. Moreover, in regions severely affected by COVID-19, vascular procedures have been reduced to life or limb salvaging cases, owing to new government directives or hospital guidelines. This measure is expected to keep hospital beds and healthcare providers available for COVID-19 patients, as well as to save personal protective equipment (PPE) and reduce viral transfer among patients and between patients and staff. All these factors are anticipated to impact the Asia-Pacific hospital-acquired infection diagnostics market as well in the future.
An increase in the number of hospital-acquired infections, especially in the developing and underdeveloped economies has surged the demand in the hospital-acquired control market. Different emerging economies such as India, China, South Africa, Brazil, and Mexico are witnessing a surge in the number of under-served patients. Economic development in these regions is creating scopes of the growth for the manufacturers on the back of a large patient pool. Growth in medical expenditure and infrastructure encouraged by the governments of the respective economies is enhancing the adoption rate of sophisticated medical devices, generating substantial revenue in the market. High demand for devices such as endoscope reprocessing devices which are capable of disinfecting medical devices is pushing ahead the boundaries of growth of the hospital-acquired infection diagnostics market. Innovations focused on avoiding cross contaminations and enhancing the patients' safety are gaining preference in the medical sector
Increase in investment in infectious disease-related researches propels the market growth. As an instance, as per the estimation of NHS in 2019, it states that NHS would invest more than USD 6 Billion on infectious disease-related research. Under such investments re-emerging diseases like tuberculosis and emerging infectious diseases like the Heartland and Bourbon viruses are taken into consideration. Increase in the number of healthcare-associated infection foster the market demand. Furthermore, it is particularly relevant for highly populated and developing regions. The growing emphasis on addressing the issue of tropical disease treatment and diagnosis in developing nations, United Nations Development Program (UNDP), World Health Organization (WHO), and United Nations Children’s Fund (UNICEF) have come up with TDR, the special program for research and training in tropical disease. The development of such special programs by various healthcare agencies is also opening new avenues for the application of various diagnostics methods supporting the growth of the market.
Rise in prevalence of population suffering from respiratory diseases, gastrointestinal infection, blood infection and others is expected to positively affect the growth of the market. Moreover, increase in initiatives undertaken by authorities and governments to improve healthcare systems and spread awareness regarding benefits of sanitization and personal hygiene are also expected to increase growth of the hospital-acquired infection diagnostics market. For instance, WHO had introduced an awareness program known as Patient Safety Solutions, in which WHO promoted hand hygiene adherence as a health care facility on priority to reduce the burden of infectious diseases. Thus, due to the introduction of various awareness programs, it is expected to create awareness among individuals regarding the hospital acquired infection, which would further create lucrative opportunities for key market vendors.
Asia-Pacific Hospital-Acquired Infection Diagnostics Market
By Test type
Molecular Diagnostics is projected as one of the most lucrative segment.
Get more information on this report : Request Sample Pages
Asia Pacific Hospital-acquired Infection Diagnostics Market Segmentation
The Asia Pacific hospital-acquired infection diagnostics market is segmented based on product, test type, infection type, end user, and region. Based on product this market is segmented into instrument and reagents & consumables. Based on test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. Further, based on infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others. Based on end user this market is segmented into hospital, clinics, and others. Country wise, the market is analyzed across India, Nepal, Bhutan, Bangladesh, Maldives, Sri Lanka, Myanmar, and Rest of Asia-Pacific.
Segment review
On the basis of products, the reagent and consumables segment is estimated to garner largest share during the forecast period. This segment is expected to maintain its dominant position throughout the forecast period. Growth of the segment is attributed to rise in the number of patients suffering from various infectious diseases and high prevalence of hospital acquired infections in low and middle income countries. In addition, by infection type, the surgical site infections segment is estimated to garner largest share during the forecast period. This attributed to the low awareness regarding HAIs among healthcare workers and rise in number of surgeries, are expected to increase its adoption rate in the future.
Asia-Pacific Hospital-Acquired Infection Diagnostics Market
By Infection type
Surgical Site Infections is projected as one of the most lucrative segment.
Get more information on this report : Request Sample Pages
By end user, the hospitals segment accounted for majority of the market share in 2019, and is anticipated to continue this trend throughout the forecast period, owing to rise in number of surgeries performed and high adoption rate of diagnostic instruments in hospitals and rise in number of patients diagnosed with infectious diseases and the high probability of infections in hospital premises through blood-borne or respiratory pathogen transmission are also anticipated to boost the market growth.
The key players operating in the Asia-Pacific hospital-acquired infection diagnostics market include BECTON, DICKINSON AND COMPANY, Cepheid, Abbott Laboratories, F. Hoffmann-LA Roche Ltd, AstraZeneca, Daiichi Sankyo Co., Ltd., Hologic, Inc., Siemens, BIOMERIEUX SA, NG Biotech.
Asia-Pacific Hospital-Acquired Infection Diagnostics Market
By Country
India country would exhibit the highest CAGR of 8.5% during 2020-2027.
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the hospital-acquired infection diagnostics market along with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
- The key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Market Segments
By Product type
- Instrument
- Consumables & Reagents
By Test Type
- Molecular Diagnostics
- Urinalysis
- Immunoassay
By Infection Type
- Hospital Acquired Pneumonia
- Bloodstream Infections
- Carbapenem Resistant Enterobacteriaceae
- Others
- Surgical Site Infections
- Methicillin Resistant Staphylococcus
- Others
- Gastrointestinal Infections
- Clostridium Difficile
- Others
- Urinary Tract Infections (UTI)
- Others
By End User
- Hospitals
- Clinics
- Others
By Country
- India
- Nepal
- Bhutan
- Bangladesh
- Maldives
- Sri Lanka
- Myanmar
- Rest of Asia Pacific
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top winning strategies, 2019
3.3.Top player positioning
3.4.Top investment pockets
3.5.Key forces shaping capnography industry/market
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Increase in geriatric population
3.6.1.2.HAIs and direct healthcare costs
3.6.1.3.Development of technologically advanced diagnostic products
3.6.1.4.Demand for hospital acquired infection diagnostics from middle and low-income countries
3.6.2.Restraints
3.6.2.1.Lack of awareness regarding hospital acquired infections
3.6.2.2.The consequences of antibiotic resistant infections
3.6.3.Opportunity
3.6.3.1.Introduction of awareness programs by various organizations
3.6.4.Impact Analysis
3.7.Impact analysis of COVID-19 on the Asia-Pacific hospital-acquired infection diagnostics market
3.7.1.Overview
3.7.2.Impact of COVID-19 on the market
CHAPTER 4:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast, by product
4.2.Instrument
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Reagents and consumables
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE
5.1.Overview
5.1.1.Market size and forecast, by test type
5.2.Molecular diagnostics
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Immunoassay
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Urinalysis
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
CHAPTER 6:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE
6.1.Overview
6.1.1.Market size and forecast, by Infection Type
6.2.Hospital acquired pneumonia
6.2.1.Market size and forecast, by country
6.2.2.Market analysis, by country
6.3.Bloodstream Infections
6.3.1.Market size and forecast, by country
6.3.2.Market analysis, by country
6.3.3.Bloodstream Infections, By type
6.3.3.1.Carbapenem Resistant Enterobacteriaceae
6.3.3.1.1.Market size and forecast, by infection type
6.3.3.1.2.Market size and forecast, by product
6.3.3.1.3.Market size and forecast, end user
6.3.3.1.4.Market size and forecast, by country
6.4.Surgical Site Infections
6.4.1.Market size and forecast, by country
6.4.2.Market analysis, by country
6.4.3.Surgical site infections, By type
6.4.3.1.Methicillin Resistant Staphylococcus
6.4.3.1.1.Market size and forecast, by infection type
6.4.3.1.2.Market size and forecast, by product
6.4.3.1.3.Market size and forecast, end user
6.4.3.1.4.Market size and forecast, by country
6.5.Gastrointestinal Infections
6.5.1.Market size and forecast, by country
6.5.2.Market analysis, by country
6.5.3.Gastrointestinal infections, By type
6.5.3.1.Clostridium Difficile
6.5.3.1.1.Market size and forecast, by infection type
6.5.3.1.2.Market size and forecast, by product
6.5.3.1.3.Market size and forecast, end user
6.5.3.1.4.Market size and forecast, by country
6.6.Urinary Tract Infections
6.6.1.Market size and forecast, by country
6.6.2.Market analysis, by country
6.7.Others
6.7.1.Market size and forecast, by country
6.7.2.Market analysis, by country
CHAPTER 7:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast, end user
7.2.Hospitals
7.2.1.Market size and forecast, by country
7.2.2.Market analysis, by country
7.3.Clinics
7.3.1.Market size and forecast, by country
7.3.2.Market analysis, by country
7.4.Others
7.4.1.Market size and forecast, by country
7.4.2.Market analysis, by country
CHAPTER 8:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY
8.1.Overview
8.1.1.Market size and forecast
8.2.India
8.2.1.Key market trends and growth opportunities
8.2.1.1.Market size and forecast, by product
8.2.1.2.Market size and forecast, test type
8.2.1.3.Market size and forecast, by Infection Type
8.2.1.4.Market size and forecast, end user
8.3.Nepal
8.3.1.Key market trends and growth opportunities
8.3.1.1.Market size and forecast, by product
8.3.1.2.Market size and forecast, test type
8.3.1.3.Market size and forecast, by Infection Type
8.3.1.4.Market size and forecast, end user
8.4.Bhutan
8.4.1.Key market trends and growth opportunities
8.4.1.1.Market size and forecast, by product
8.4.1.2.Market size and forecast, test type
8.4.1.3.Market size and forecast, by Infection Type
8.4.1.4.Market size and forecast, end user
8.5.Bangladesh
8.5.1.Key market trends and growth opportunities
8.5.1.1.Market size and forecast, by product
8.5.1.2.Market size and forecast, test type
8.5.1.3.Market size and forecast, by Infection Type
8.5.1.4.Market size and forecast, end user
8.6.Maldives
8.6.1.Key market trends and growth opportunities
8.6.1.1.Market size and forecast, by product
8.6.1.2.Market size and forecast, test type
8.6.1.3.Market size and forecast, by Infection Type
8.6.1.4.Market size and forecast, end user
8.7.Sri Lanka
8.7.1.Key market trends and growth opportunities
8.7.1.1.Market size and forecast, by product
8.7.1.2.Market size and forecast, test type
8.7.1.3.Market size and forecast, by Infection Type
8.7.1.4.Market size and forecast, end user
8.8.Myanmar
8.8.1.Key market trends and growth opportunities
8.8.1.1.Market size and forecast, by product
8.8.1.2.Market size and forecast, test type
8.8.1.3.Market size and forecast, by Infection Type
8.8.1.4.Market size and forecast, end user
8.9.Rest of Asia-Pacific
8.9.1.Key market trends and growth opportunities
8.9.1.1.Market size and forecast, by product
8.9.1.2.Market size and forecast, test type
8.9.1.3.Market size and forecast, by Infection Type
8.9.1.4.Market size and forecast, end user
CHAPTER 9:COMPANY PROFILES
9.1.ABBOTT LABORATORIES
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.ASTRAZENECA
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Product portfolio
9.2.4.Business performance
9.3.BECTON, DICKINSON AND COMPANY
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.BIOMERIEUX SA
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Product portfolio
9.4.4.Business performance
9.5.CEPHEID
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.6.DAIICHI SANKYO CO., LTD.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Product Portfolio
9.6.4.Business performance
9.6.5.Key strategic moves and developments
9.7.F. HOFFMANN-LA ROCHE LTD.
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segment
9.7.4.Product portfolio
9.7.5.Business performance
9.7.6.Key strategic moves and developments
9.8.HOLOGIC, INC.
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.NG BIOTECH
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Key strategic moves and developments
9.10.SIEMENS
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INSTRUMENT, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 03.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REAGENTS AND CONSUMABLES, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 04.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 05.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 06.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 07.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 08.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 09.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 10.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BLOODSTREAM INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 11.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 12.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 13.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY END USER, 2019–2027 ($MILLION)
TABLE 14.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 15.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SURGICAL SITE INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 16.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 17.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 18.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY END USER, 2019–2027 ($MILLION)
TABLE 19.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 22.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 23.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY END USER, 2019–2027 ($MILLION)
TABLE 24.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 25.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR URINARY TRACT INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 27.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 28.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 29.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLINICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 30.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 31.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 32.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 33.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 34.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 35.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY END USER, 2019–2027 ($MILLION)
TABLE 36.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 37.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 38.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 39.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY END USER, 2019–2027 ($MILLION)
TABLE 40.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 41.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 42.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 43.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY END USER, 2019–2027 ($MILLION)
TABLE 44.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 45.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 46.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 47.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY END USER, 2019–2027 ($MILLION)
TABLE 48.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 49.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 50.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 51.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES, BY END USER, 2019–2027 ($MILLION)
TABLE 52.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 53.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 54.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 55.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY END USER, 2019–2027 ($MILLION)
TABLE 56.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY END USER, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 61.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 62.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 63.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY END USER, 2019–2027 ($MILLION)
TABLE 64.ABBOTT: COMPANY SNAPSHOT
TABLE 65.ABBOTT: OERATING SEGMENT
TABLE 66.ABBOTT: PRODUCT PORTFOLIO
TABLE 67.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 69.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 70.BD: SNAPSHOT
TABLE 71.BD: OPERATING SEGMENTS
TABLE 72.BD: PRODUCT PORTFOLIO
TABLE 73.BIOMERIEUX: COMPANY SNAPSHOT
TABLE 74.BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 75.CEPHEID: COMPANY SNAPSHOT
TABLE 76.CEPHEID: OPERATING BUSINESS SEGMENTS
TABLE 77.CEPHEID: PRODUCT PORTFOLIO
TABLE 78.DAIICHI SANKYO: COMPANY SNAPSHOT
TABLE 79.DAIICHI SANKYO: PRODUCT PORTFOLIO
TABLE 80.ROCHE: COMPANY SNAPSHOT
TABLE 81.ROCHE: OPERATING SEGMENT
TABLE 82.ROCHE: PRODUCT PORTFOLIO
TABLE 83.HOLOGIC: COMPANY SNAPSHOT
TABLE 84.HOLOGIC: OPERATING BUSINESS SEGMENTS
TABLE 85.HOLOGIC: PRODUCT PORTFOLIO
TABLE 86.NG BIOTECH: COMPANY SNAPSHOT
TABLE 87.NG BIOTECH: OPERATING SEGMENTS
TABLE 88.NG BIOTECH: PRODUCT PORTFOLIO:
TABLE 89.SIEMENS: COMPANY SNAPSHOT
TABLE 90.SIEMENS: OPERATING SEGMENTS
TABLE 91.SIEMENS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017–2020*
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES: COMPANY , 2017–2020
FIGURE 05.TOP PLAYER POSITIONING, 2019
FIGURE 06.TOP INVESTMENT POCKETS
FIGURE 07.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.HIGH THREAT OF SUBSTITUTES
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.MODERATE THREAT OF NEW ENTRANTS
FIGURE 12.IMPACT ANALYSIS, ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET
FIGURE 13.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INSTRUMENT, BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REAGENTS AND CONSUMABLES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BLOODSTREAM INFECTIONS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SURGICAL SITE INFECTIONS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR URINARY TRACT INFECTIONS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR HOSPITAL, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLINICS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 29.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 30.ASTRAZENECA: NET SALES, 2017–2019 ($MILLION)
FIGURE 31.ASTRAZENECA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.BD: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 34.BECTON, DICKINSON AND COMPANY REVENUE SHARE BY REGION, 2019 (%)
FIGURE 35.NET SALES, 2017–2019 ($MILLION)
FIGURE 36.BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 37.BIOMERIEUX: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 38.DAIICHI SANKYO: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.DAIICHI SANKYO: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 40.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43.HOLOGIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.HOLOGIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 45.HOLOGIC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 46.SIEMENS: NET SALES, 2016–2018 ($MILLION)
FIGURE 47.SIEMENS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48.SIEMENS: REVENUE SHARE BY REGION, 2018(%)
According to the analyst’s, the hospital-acquired infection diagnostics market is expected to witness a steady growth rate during the forecast period. The large-scale use of disinfectors and medical nonwovens in the healthcare industry, rise in emphasis on infection control policies within hospital premises, surge in geriatric population, and increase in number of surgeries performed across the Asia-Pacific region are expected to propel the growth of this market. However, the increase in healthcare cost and prevalence of antibiotic resistant infections impedes the market growth.
Rise in incidences of chronic disease, lung diseases, growth in aging population, and increase in ICU admission are some of the factors that majorly drive the market growth.
According to the perspectives of analyst’s, the hospital-acquired infection diagnostics market is dominated by well-established players; hence there is intense competition in the Asia Pacific market. There is a high adoption of these devices owing to increase in prevalence of infectious diseases, which propels the market growth. In addition, technological advancements is prevalent in the market thus, there is an increase in product launches, due to which the market is estimated to grow with a high CAGR. India and Bangladesh are expected to offer lucrative growth opportunities to the key players in the industry.
Q1. What is the total market value of Asia Pacific Hospital Acquired Infection Diagnostics Market report ?
A. The total market value of Asia Pacific Hospital Acquired Infection Diagnostics Market is $418.937 million in 2019.
Q2. What would be forecast period in the market report?
A. The forecast period for Asia Pacific Hospital Acquired Infection Diagnostics Market is 2020 to 2027
Q3. What is the market value of Asia Pacific Hospital Acquired Infection Diagnostics Market in 2027?
A. The market value of Asia Pacific Hospital Acquired Infection Diagnostics Market in 2027 is $780.882 million.
Q4. Which is base year calculated in the Asia Pacific Hospital Acquired Infection Diagnostics Market report?
A. The base year is 2019 in Asia Pacific Hospital Acquired Infection Diagnostics Market
Q5. Which are the top companies hold the market share in Asia Pacific Hospital Acquired Infection Diagnostics Market?
A. Top companies such as Abbott Laboratories, F. Hoffmann-LA Roche Ltd., Siemens, Biomerieux SA, Becton, Dickinson And Company held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Q6. Which is the most influencing segment growing in the Asia Pacific Hospital Acquired Infection Diagnostics Market report?
A. In test type segment molecular diagnostics is the most influencing segment. Hence, increase in the prevalence of the infectious diseases, increase in awareness and acceptance of personalized medicines, and growth in the biomarker identification drive the growth of this market. In addition, increase in adoption of the molecular diagnostics in the emerging economies act as an opportunity for the market growth.
Q7. What are the key trends in the Asia Pacific Hospital Acquired Infection Diagnostics Market report?
A. The major factor that fuels the growth of the global Asia Pacific Hospital Acquired Infection Diagnostics Market includes Increase in geriatric population and Development of technologically advanced diagnostic products, rise in geriatric population, and others. furthermore, Demand for hospital acquired infection diagnostics from middle and low-income countries. This leads to surge in demand for hospital acquired infection diagnostics product which contribute to the growth of the market.
Q8. What are the market values / growth % of emerging countries?
A. India has the highest growth rate in the market which is growing due to the contribution of the emerging country. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & clinics equipped with advanced medical facilities.
Q9. What is Hospital Acquired Infections?
A. A Hospital-acquired infection also known as a nosocomial infection, is an infection that is acquired in a hospital or other health care facility To emphasize both hospital and nonhospital settings, it is sometimes instead called a healthcare associated infection.
Q10. What are the common hospital acquired infections?
A. Hospital-acquired infections are caused by viral, bacterial, and fungal pathogens; the most common types are bloodstream infection (BSI), pneumonia (eg, ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI).
Download Sample
Purchase Full Report of
Asia-Pacific Hospital-Acquired Infection Diagnostics Market
- Online Only
-
$3,712$3,341 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Data Pack
-
$4,125$3,713 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Single User
-
$6,168$5,243 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
15%
Discount
- Five Users
-
$6,929$5,543 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
20%
Discount
-
Enterprise
License/PDF -
$9,663$7,247 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
25%
Discount
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading instantly.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers